Bevacizumab vs ranibizumab treatment for age-related macular degeneration - A head-to-head comparison is needed

被引：2
|
作者：
Jampol, Lee M. [1 ]
机构：
[1] Northwestern Univ, Feinberg Sch Med, Dept Ophthalmol, Chicago, IL 60611 USA
来源：
ARCHIVES OF OPHTHALMOLOGY | 2007年 / 125卷 / 04期
关键词：
D O I：
10.1001/archopht.125.4.557
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
引用
收藏
页码：557 / 558
页数：2
相关论文
共 50 条
  • [31] A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration
    Park, Dae Hyun
    Sun, Hae Jung
    Lee, Sung Jin
    INTERNATIONAL OPHTHALMOLOGY, 2017, 37 (05) : 1205 - 1214
  • [32] Comparison of bevacizumab and ranibizumab in age-related macular degeneration: a systematic review and meta-analysis
    Zhang, Xiao-Yu
    Guo, Xiao-Fan
    Zhang, Shao-Dan
    He, Jing-Na
    Sun, Cao-Yu
    Zou, Yin
    Bi, Han-Si
    Qu, Yang
    INTERNATIONAL JOURNAL OF OPHTHALMOLOGY, 2014, 7 (02) : 355 - 364
  • [33] COST COMPARISON OF WET AGE-RELATED MACULAR DEGENERATION TREATMENT WITH AFLIBERCEPT OR RANIBIZUMAB
    Gerasimova, K.
    Derkach, E., V
    VALUE IN HEALTH, 2016, 19 (07) : A567 - A567
  • [34] EFFICACY AND SAFETY OF RANIBIZUMAB AND BEVACIZUMAB IN TREATMENT FOR AGE RELATED MACULAR DEGENERATION
    Saturnino, L. T. M.
    Silveira, M. R.
    Guerra Junior, A. A.
    Acurcio, F. D. A.
    VALUE IN HEALTH, 2013, 16 (07) : A667 - A668
  • [35] Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration Two-Year Results
    Martin, Daniel F.
    Maguire, Maureen G.
    Fine, Stuart L.
    Ying, Gui-shuang
    Jaffe, Glenn J.
    Grunwald, Juan E.
    Toth, Cynthia
    Redford, Maryann
    Ferris, Frederick L.
    OPHTHALMOLOGY, 2020, 127 (04) : S135 - S145
  • [36] Anterior uveitis after treatment of age-related macular degeneration with ranibizumab and bevacizumab: uncommon complication
    Damasceno, Nadyr
    Horowitz, Soraya
    Damasceno, Eduardo
    CLINICAL OPHTHALMOLOGY, 2012, 6 : 1201 - 1205
  • [37] The efficacy of aflibercept in the treatment of neovascular age-related macular degeneration previously treated with bevacizumab or ranibizumab
    Hall, Laura
    Zebardast, Nazlee
    Adelman, Ron
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2013, 54 (15)
  • [38] COST UTILITY ANALYSIS OF AFLIBERCEPT, RANIBIZUMAB, AND BEVACIZUMAB FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
    Lin, C. W.
    Hay, J.
    VALUE IN HEALTH, 2014, 17 (03) : A287 - A287
  • [39] Comparison of antiangiogenic agents (ranibizumab, aflibercept, bevacizumab and ziv-aflibercept) in the therapeutic response to the exudative form of age-related macular degeneration according to the treat-and-extend protocol- true head-to-head study
    Kanadani, Tereza
    Rabelo, Neiffer
    Takahashi, Denise
    Magalhaes, Lucas
    Farah, Michel
    INTERNATIONAL JOURNAL OF RETINA AND VITREOUS, 2024, 10 (01)
  • [40] Comparison of antiangiogenic agents (ranibizumab, aflibercept, bevacizumab and ziv-aflibercept) in the therapeutic response to the exudative form of age-related macular degeneration according to the treat-and-extend protocol- true head-to-head study
    Tereza Kanadani
    Neiffer Rabelo
    Denise Takahashi
    Lucas Magalhães
    Michel Farah
    International Journal of Retina and Vitreous, 10
12345